ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2026
Positive surgical margins after robot-assisted radical prostatectomy Long-term oncologic consequences.
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe aimed to evaluate the prognostic significance of positive surgical margins (PSM) and associated clinicopathologic factors on long-term oncologic outcomes following robot-assisted radical prostatectomy (RARP).
methodsWe analyzed a prospectively maintained registry of patients undergoing RARP between 2003 and 2022, stratified by surgical margin status (positive vs. negative [NSM]). Primary outcomes were overall survival (OS) and biochemical recurrence-free survival (BCRFS). Multivariable Cox regression adjusted for age, prostate-specific antigen (PSA), Gleason grade group (GGG), pathologic stage, nodal status, and adjuvant therapy. A prognostic nomogram for OS was developed in the PSM cohort.
resultsAmong 3969 patients, 459 (11.4%) had PSM, which was more common in the presence of adverse pathologic features. On unadjusted analysis, PSM was associated with worse OS (hazard ratio [HR] 1.39, 95% confidence interval [CI] 1.02-1.90, p=0.036) and BCRFS (HR 2.20, 95% CI 1.62-2.97, p<0.001). After adjustment, PSM was not independently associated with OS (adjusted [a]HR 1.16, p=0.377) or BCRFS (aHR 0.86, p=0.343). In the PSM cohort, ≥pT3a disease, node-positive status, and advanced pathologic stage were strong predictors of mortality (HRs 3.91, 3.86, and 3.62, respectively), while adjuvant radiation therapy was associated with improved survival (HR 0.46, p=0.025). The PSM-specific nomogram demonstrated time-dependent area under the curve (AUC) of 0.737 (3 years), 0.713 (5 years), 0.774 (10 years), and 0.932 (20 years).
conclusionsPSMs are associated with worse unadjusted outcomes, largely driven by their association with high-risk pathologic features, but are not independently prognostic after accounting for tumor biology and disease stage. A PSM-specific nomogram may support individualized postoperative risk stratification and shared decision-making, pending external validation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.